[Clinical studies of sulbactam/cefoperazone in the field of obstetrics and gynecology].
Sulbactam (SBT), a new beta-lactamase inhibitor, in combination with cefoperazone (CPZ) was studied for the clinical evaluation in the field of obstetrics and gynecology. SBT/CPZ was given to 6 cases with the following infections; 4 of pyometra, 1 of Douglas-abscess and 1 of pelvic cellulitis. Five cases were old patients accompanied by cancers, and 2 cases were refractory to other antibiotics therapy. The clinical efficacy was excellent in 1 case, good in 3 cases, poor in 2 cases. No side effects nor abnormal laboratory findings associate with the agent were observed.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002438:Cefoperazone / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D010397:Penicillanic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D013407:Sulbactam; D065093:beta-Lactamase Inhibitors
D004338:Drug Combinations; D065093:beta-Lactamase Inhibitors; D002438:Cefoperazone; D010397:Penicillanic Acid; D013407:Sulbactam